The Impact of Dosimetry Extrapolation Methods for Theranostic Applications of Fibrosing Mediastinitis
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00635 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Liwei Song und 13 weiteren Autor:innen. Beteiligte Einrichtung: First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan 030001, China. Hauptthemen laut MEDLINE: Mediastinitis, Radiometry, Sclerosis, Theranostic Nanomedicine. Die Arbeit nennt 58 Literaturangaben. Gefördert von: Natural Science Foundation for Young Scientists of Shanxi Province, Shanxi Scholarship Council of China, Local Science and Technology Development Guided by the Central Government.
Abstract (Originalsprache)
Fibrosing mediastinitis (FM) is a benign but potentially fatal condition characterized by excessive fibrous tissue proliferation in the mediastinum, leading to compression of vital structures. A radioisotope-based therapeutic approach using 177Lu-FAPI-46 has demonstrated promising results in preclinical models; however, the lack of animal-to-human dosimetry data has hindered clinical translation. In this study, we aimed to evaluate various animal-to-human dosimetry extrapolation methods to support the potential clinical use of 177Lu-FAPI-46 in FM treatment. Five extrapolation methods were investigated, including direct application of rat time-integrated activity coefficients (TIACs) to human organs (M1), relative mass scaling (M2), metabolic rate scaling (M3), combined mass and metabolic rate scaling (M4), and organ-specific allometric scaling (M5). The correlation between these methods and uterine uptake, as well as clinical imaging data, was further analyzed. Notable variability was observed in the estimated absorbed dose distribution across organs using the different methods, with higher uptake consistently noted in the intestines, kidneys, ovaries, and uterus. Physiological uptake in the uterus, ovaries, and small intestine was confirmed, and the uterus was identified as the dose-limiting organ, with the maximum permissible administered activity estimated to be below 2.78 GBq. Extrapolated absorbed dose estimates suggest that a uterine dose of 16 Gy could be reached with an administered activity of less than 2.78 GBq, depending on the dosimetry model used. These findings highlight the necessity of careful dose planning and special consideration for protecting reproductive organs, particularly in younger female patients, during future clinical trials of 177Lu-FAPI-46 for FM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan 030001, China.
- Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China.
- Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan 030001, China.
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna 1090, Austria.
- Division of Radiation Medicine and Environmental Medicine, China Institute of Radiation Protection, Taiyuan 030006, China.
- Shanxi Key Laboratory of Drug Toxicology and Preclinical Studies for Radiopharmaceutical, Taiyuan 030006, China.
ORCID-Profile: Liwei Song, Sijin Li, Zhifang Wu
Förderung
- Natural Science Foundation for Young Scientists of Shanxi Province
- Shanxi Scholarship Council of China
- Local Science and Technology Development Guided by the Central Government
- Research and Innovation Team Project for Scientific Breakthrough at Shanxi Bethune Hospital
Zitieren
APA
Song, L., Chen, X., Li, X., Han, Z., Zhang, S., Zhang, M., Zhang, L., Lan, L., Li, S., Cao, J., Hacker, M., Shi, Y., Li, J., & Wu, Z. (2025). The Impact of Dosimetry Extrapolation Methods for Theranostic Applications of Fibrosing Mediastinitis. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00635
Vancouver
Song L, Chen X, Li X, Han Z, Zhang S, Zhang M, et al. The Impact of Dosimetry Extrapolation Methods for Theranostic Applications of Fibrosing Mediastinitis. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00635
BibTeX
@article{Song2025,
author = {Song, Liwei and Chen, Xufu and Li, Xiang and Han, Zongtai and Zhang, Shu and Zhang, Meiling and Zhang, Liyun and Lan, Lizhen and Li, Sijin and Cao, Jianbo and Hacker, Marcus and Shi, Yiwei and Li, Jianguo and Wu, Zhifang},
title = {The Impact of Dosimetry Extrapolation Methods for Theranostic Applications of Fibrosing Mediastinitis},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00635}
}
EUVIMED